CC-97489, CC-97489, CC-97489 1mg , CC-97489 3mg
IM045-1018
Phase 2 small_molecule active
Quick answer
CC-97489, CC-97489, CC-97489 1mg , CC-97489 3mg for Multiple Sclerosis Spasticity is a Phase 2 program (small_molecule) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Celgene Europe Limited
- Indication
- Multiple Sclerosis Spasticity
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active